Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy.

about

Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy.

Item

http://www.wikidata.org/entity/Q49379624

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Uncommon EGFR mutations in a c ...... d platinum-based chemotherapy.

@en

Uncommon EGFR mutations in a c ...... d platinum-based chemotherapy.

@nl

type

Item

label

Uncommon EGFR mutations in a c ...... d platinum-based chemotherapy.

@en

Uncommon EGFR mutations in a c ...... d platinum-based chemotherapy.

@nl

prefLabel

Uncommon EGFR mutations in a c ...... d platinum-based chemotherapy.

@en

Uncommon EGFR mutations in a c ...... d platinum-based chemotherapy.

@nl

P1476

Uncommon EGFR mutations in a c ...... d platinum-based chemotherapy.

@en

P2093

Caicun Zhou

http://www.w3.org/2001/XMLSchema#string

Chao Zhao

http://www.w3.org/2001/XMLSchema#string

Chunxia Su

http://www.w3.org/2001/XMLSchema#string

Hui Yang

http://www.w3.org/2001/XMLSchema#string

Jinpeng Shi

http://www.w3.org/2001/XMLSchema#string

Lei Xi

http://www.w3.org/2001/XMLSchema#string

Limin Zhang

http://www.w3.org/2001/XMLSchema#string

Sha Zhao

http://www.w3.org/2001/XMLSchema#string

Shengxiang Ren

http://www.w3.org/2001/XMLSchema#string

Shijia Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P304

543-552

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21147/J.ISSN.1000-9604.2017.06.09

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29353977

http://www.w3.org/2001/XMLSchema#string

P932

5775013

http://www.w3.org/2001/XMLSchema#string